xxiv
Project euHeart for Personalized Management of Heart Disease ......... 506
Concluding Remarks on Personalized Management
of Cardiovascular Diseases ................................................................... 507
References ................................................................................................. 50715 Personalized Management of Pulmonary Disorders ........................... 511
Introduction ............................................................................................... 511
Role of Genetic Ancestory in Lung Function ....................................... 511
Biomarkers of Pulmonary Disorders ........................................................ 512
Biomarkers of Infl ammation and Lung Function in the Elderly ........... 513
Biomarkers of Oxidative Stress in Lung Diseases ................................ 513
Biomarkers of Community-Acquired Pneumonia ................................ 513
Personalized Therapy of Asthma .............................................................. 515
Biomarkers of Asthma .......................................................................... 515
Genotyping in Asthma .......................................................................... 519
Lebrikizumab for Personalized Treatment of Asthma .......................... 520
Personalized Therapy of Chronic Obstructive Pulmonary Disease .......... 521
Biomarkers of COPD ............................................................................ 521
Gene Expression Studies of Lung Tissue in COPD .............................. 523
Prognosis of COPD ............................................................................... 524
Management of COPD .......................................................................... 524
Personalized Management of Interstitial Lung Disease ............................ 525
Biomarkers of Interstitial Lung Disease ............................................... 525
Developing Personalized Therapies for Interstitial Lung Disease ........ 526
References ................................................................................................. 527
16 Personalized Management of Genetic Disorders ................................. 529
Introduction ............................................................................................... 529
Molecular Diagnosis of Genetic Disorders ............................................... 529
Molecular Diagnostic Technologies ...................................................... 530
Biomarkers for Genetic Disorders ............................................................ 534
Biomarkers for Down’s Syndrome ....................................................... 534
Biomarkers for Muscular Dystrophy .................................................... 535
Biomarkers of Phenylketonuria ............................................................ 536
Genetic Biomarkers for Psoriasis .......................................................... 536
Biomarkers of Lysosomal Storage Disorders ....................................... 537
Sequencing in Genetic Disorders .............................................................. 538
DNA Sequencing for Prenatal Disorders .............................................. 539
Study of Rare Variants in Pinpointing Disease-Causing Genes ............ 542
Personalized Cell and Gene Therapies of Genetic Disorders ................... 543
Personalized Stem Cell Transplant for Sickle Cell Anemia.................. 543
Hurler Syndrome ................................................................................... 544
Personalized Gene Therapy of Duchenne Muscular Dystrophy ........... 544
Personalized Treatment of Cystic Fibrosis ............................................... 547
Current Management of CF .................................................................. 547
Contents